CompletedNot Applicable

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

Belarus, Russia230 participantsStarted 2024-03-18

Plain-language summary

Esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure. However, esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All consecutive patients with clinically documented primary Esophageal or Esophagogastric Junction malignancy (including Siewert I and II) undergoing elective surgery with curative intent - via open, laparoscopic or robotic approach between 18th March 2024 and 18th September 2024 Exclusion Criteria: * Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers. * Esophagogastric Junction Siewert III malignancy * Patients submitted to Emergency surgery or surgery without curative intent * Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy

What they're measuring

the type of complications and the incidence of it

Timeframe: within 90 days after operation

Trial details

NCT IDNCT06277921

SponsorP. Herzen Moscow Oncology Research Institute

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-09-18

View on ClinicalTrials.gov More Esophageal Cancer trials